BiomarkersFDA Approvals, News & Updates

Tabrecta Approved for NSCLC with MET Biomarker

In May 2020, the FDA approved Tabrecta, a new targeted therapy for the treatment of patients with metastatic non–small-cell lung cancer that is associated with the MET biomarker.
June 2020 Vol 6 No 3

On May 6, 2020, the FDA approved Tabrecta (capmatinib; from Novartis), an oral kinase inhibitor, for adults with metastatic (spreading) non–small-cell lung cancer (NSCLC).

To be able to receive Tabrecta, patients must be tested to identify this biomarker (or mutation). Therefore, on the same day, the FDA also approved the Foundation

One CDx assay as a diagnostic test for Tabrecta.

“Tabrecta is the first approval specifically for the treatment of patients with non–small-cell lung cancer whose tumors have mutations that lead to MET exon 14 skipping. This patient population now has an option for a targeted therapy,” said Richard Pazdur, M.D., Director of the FDA’s Oncology Center of Excellence.

The clinical trial that led to the approval of Tabrecta included patients with NSCLC and the MET biomarker; patients were not included if they had EGFR or ALK gene mutations.

Among the 28 patients who had never received treatment for NSCLC, the overall response was 68%, including 4% complete responses and 64% partial responses. Among the 69 patients who received previous therapy, 41% had a partial response to Tabrecta. Moreover, 47% of the patients who received Tabrecta as first treatment versus 32.1% of patients who had previously received other NSCLC therapy responded to Tabrecta.

The most common side effects with Tabrecta were rash, nausea, fatigue, vomiting, shortness of breath, and reduced appetite. The serious side effects included interstitial lung disease or pneumonitis.

Recommended For You
FDA Approvals, News & Updates
On August 5, 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
FDA Approvals, News & Updates
Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer
In June, the FDA approved Zepzelca as the newest treatment for patients with metastatic small-cell lung cancer, an uncommon type of lung cancer with few treatment options.
BiomarkersBreast CancerSurvivorship
Surviving Pregnancy and Breast Cancer
By Kelsey Moroz
With her family history of cancers related to the BRCA mutation, Jamie Ledezma’s first pregnancy suddenly got very complicated when she learned she had triple-negative breast cancer.
Breast CancerFDA Approvals, News & Updates
Trodelvy New Therapy Approved for Triple-Negative Breast Cancer
In April, 2020, the FDA approved Trodelvy for the treatment of adults with metastatic triple-negative breast cancer after 2 or more previous therapies.
Last modified: August 10, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.